Epizyme, Inc. (EPZM)
Stock Price:
$13.32 USD
-0.25 (-1.84%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $13.30 -0.02 (-0.15%) Oct 23, 6:58 PM
Key Info
| Market Cap |
1.35B |
| Revenue (ttm) |
13.83M |
| Net Income (ttm) |
-201.88M |
| Shares Out |
101.48M |
| EPS (ttm) |
-2.00 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$13.32 |
| Previous Close |
$13.57 |
| Change ($) |
-0.25 |
| Change (%) |
-1.84% |
| Day's Open |
13.70 |
| Day's Range |
13.13 - 13.81 |
| Day's Volume |
824,713 |
| 52-Week Range |
10.51 - 27.82 |
More Stats
| Market Cap |
1.35B |
| Enterprise Value |
1.12B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
101.48M |
| Float |
87.23M |
| EPS (basic) |
-2.09 |
| EPS (diluted) |
-2.00 |
| FCF / Share |
-2.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.38M |
| Short Ratio |
11.07 |
| Short % of Float |
11.90% |
| Beta |
1.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
97.74 |
| PB Ratio |
5.35 |
| Revenue |
13.83M |
| Operating Income |
-204.36M |
| Net Income |
-201.88M |
| Free Cash Flow |
-235.14M |
| Net Cash |
232.03M |
| Net Cash / Share |
2.29 |
| Gross Margin |
-786.92% |
| Operating Margin |
-1,477.67% |
| Profit Margin |
-1,459.70% |
| FCF Margin |
-1,700.25% |
| ROA |
-31.98% |
| ROE |
-65.22% |
| ROIC |
-71.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$27.62*
(107.36% upside)
Low
16.0
Current: $13.32
High
36.0
Target: 27.62
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 23.80 | 21.70 | 10.00 | 8.01 | 2.56 | 41.41 | 68.48 | 45.22 | 6.94 |
| Revenue Growth | 9.68% | 117% | 24.89% | 212.77% | -93.82% | -39.53% | 51.44% | 551.24% | - |
| Gross Profit | 23.80 | 21.70 | 10.00 | 8.01 | 2.56 | 41.41 | 68.48 | 45.22 | 6.94 |
| Operating Income | -177 | -128 | -137 | -112 | -133 | -55.05 | -3.13 | -0.77 | -20.97 |
| Net Income | -170 | -124 | -134 | -110 | -132 | -55.01 | -3.48 | -0.70 | -20.96 |
| Shares Outstanding | 89.89 | 71.86 | 61.47 | 57.13 | 39.84 | 33.03 | 17.05 | 1.65 | 1.43 |
| Earnings Per Share | -1.93 | -1.72 | -2.18 | -1.93 | -3.32 | -1.67 | -0.22 | -0.72 | -14.65 |
| Operating Cash Flow | -147 | -122 | -120 | -96.37 | -72.93 | -35.36 | -53.73 | 44.15 | 10.00 |
| Capital Expenditures | -0.59 | -0.30 | -0.98 | -0.62 | -0.18 | -2.22 | -0.63 | -1.48 | -0.92 |
| Free Cash Flow | -148 | -122 | -121 | -97.00 | -73.11 | -37.58 | -54.36 | 42.67 | 9.08 |
| Cash & Equivalents | 381 | 240 | 276 | 242 | 208 | 190 | 124 | 97.98 | 33.34 |
| Total Debt | 45.47 | - | 0.11 | 0.73 | 1.29 | - | - | - | - |
| Net Cash / Debt | 336 | 240 | 276 | 241 | 207 | 190 | 124 | 97.98 | 33.34 |
| Assets | 425 | 276 | 289 | 252 | 218 | 199 | 163 | 104 | 37.36 |
| Liabilities | 93.45 | 42.49 | 53.99 | 50.74 | 48.37 | 38.92 | 58.68 | 155 | 88.00 |
| Book Value | 331 | 233 | 235 | 202 | 170 | 160 | 104 | -51.13 | -50.64 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Epizyme, Inc. |
| Country |
United States |
| Employees |
203 |
| CEO |
Robert B. Bazemore |
Stock Information
| Ticker Symbol |
EPZM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EPZM |
| IPO Date |
May 31, 2013 |
Description
Epizyme, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.